狭心症エピソードの1週間当たりの回数（最小二乗平均）は、ベースラインにおいてはranolazine群が6.6回、プラセボ群が6.8回と有意差はなかった（P＝0.54）。本試験の主要評価項目である2～8週後の回数はそれぞれ3.8回、4.3回と、両群とも減少したが、有意な ...

2型糖尿病、冠動脈疾患（CAD）、慢性安定狭心症を合併し、既存の狭心症治療薬を1～2種類服用しても症状を抑制できていなかった患者を対象に、ranolazineの有効性と安全性を前向きに検討するTERISA試験が行われた。研究グループを代表して米国Saint Luke’s Mid ...

Background— Ranolazine (Ran), an antianginal agent, inhibits late Na + current. The purpose of this study was to determine whether there was an added benefit of adding Ran to cardioplegia (CP) in a ...

Background— Ranolazine has been shown to reduce myocardial ischemia and symptom severity among selected patients with chronic angina. However, data regarding the effect of ranolazine on health ...

Atrial fibrillation (AF) may arise out of anomalous impulse activity at atrial venous junctions. Triggered activity may be a source of abnormal impulse activity. Ranolazine is an anti-anginal agent, ...

Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. High dose oral anti-arrhythmics may cardiovert some paroxysmal AF. This "pill in pocket" approach has allowed patients to ...

Exposure to ranolazine is not affected by food. Oral bioavailability is in the range of 30% to 55%. Plasma protein binding (mainly to α1-acid glycoprotein) is &65%. The cytochrome P450 (CYP) ...

Please provide your email address to receive an email when new articles are posted on . At 6 months, ranolazine decreased HbA1c and improved angina frequency in patients with uncontrolled diabetes who ...